Pricing Log in Create free account

ArriVent BioPharma, Inc. (AVBP) vs Immix Biopharma, Inc. (IMMX)

ArriVent BioPharma, Inc. and Immix Biopharma, Inc. are both Biotechnology companies. ArriVent BioPharma, Inc. and Immix Biopharma, Inc. are of similar size ($603.0M and $596.9M). Across the 8 metrics below, Immix Biopharma, Inc. leads on 6 and ArriVent BioPharma, Inc. on 2.

Valuation

Metric AVBP IMMX Biotechnology median
P/E n/m n/m 10.60
P/S n/m n/m 9.40
P/B 1.77 2.23 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m n/m 9.02
Earnings yield (26.92%) (10.97%) (32.88%)
Free cash flow yield (22.81%) (7.64%) (23.13%)

Profitability

Metric AVBP IMMX Biotechnology median
Gross margin — — 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (53.10%) (34.18%) (51.96%)
Return on assets (49.30%) (31.34%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AVBP IMMX Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) (68.75%) (17.11%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric AVBP IMMX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 14.16 25.13 4.97
Net debt to EBITDA 1.73 3.39 1.01

Dividend

Metric AVBP IMMX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AVBP IMMX Biotechnology median
Market cap 603.03m 596.90m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack